Abcellera Biologics, Inc. (ABCL)
NASDAQ:ABCL
Want to see ABCL full AI Analyst Report?
ABCL Stock Chart & Stats
$4.01
-$0.28(-8.54%)
At close: 4:00 PM EST
$4.01
-$0.28(-8.54%)
Day’s Range― - ―
52-Week Range$2.75 - $6.79
Previous CloseN/A
Volume1.71M
Average Volume (3M)7.93M
Market Cap
$1.69B
Enterprise Value$1.72B
Total Cash (Recent Filing)$504.73M
Total Debt (Recent Filing)$140.18M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Aug 06, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding305,375,400
10 Day Avg. Volume5,459,703
30 Day Avg. Volume7,928,939
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue21.77
Enterprise Value/Gross Profit27.53
Enterprise Value/Ebitda-10.94
Forecast
1Y Price Target
$9.40Price Target Upside134.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$33.21M
Bulls Say, Bears Say
Bulls Say
Integrated Antibody Discovery PlatformAbCellera’s integrated discovery stack (single-cell screening, microfluidics, computational workflows) is a durable technical moat that speeds identification and optimization of antibody leads. This supports high throughput partnerships, repeat collaborations and positions the company to win discovery mandate economics over multiple years.
Strong Liquidity And Secured FundingA multi-hundred million dollar liquidity cushion and committed government funding materially lengthen runway, enabling sustained internal R&D investment and partnership execution without near-term financing pressure. This reduces dilution risk and allows multi-year development cadence for clinical programs.
Near-term Clinical Catalysts With Promising Phase I DataClear Phase II timing for ABCL635 and supportive Phase I signals provide durable de-risking milestones: a positive Phase II readout can validate target biology, unlock partner milestones/royalties, and substantiate the discovery platform’s clinical translation potential over the next 2–6+ months.
Bears Say
Sustained Cash Burn And Negative Cash FlowOperating and free cash flows remain negative, meaning the business is not yet self-funding. Over time this necessitates continued reliance on existing liquidity, milestone receipts or external financing, which can dilute shareholders or divert management focus from long‑term R&D priorities.
Small And Shifting Near-term Revenue BaseA modest research-fee revenue base that is expected to decline as the company prioritizes internal programs increases near-term top-line volatility. This structural shift raises dependence on milestone and royalty monetization that may be lumpy and realized only after lengthy development timelines.
Ongoing Clinical And Tolerability RiskLead-program clinical risk remains material: limited repeat-dose visibility and a potential tolerability signal can constrain dosing and efficacy readouts. Until positive pivotal‑stage data confirm benefit and safety, program progression and associated partner milestones/royalties remain uncertain.
AbCellera Biologics News
ABCL FAQ
What was Abcellera Biologics, Inc.’s price range in the past 12 months?
Abcellera Biologics, Inc. lowest stock price was $2.75 and its highest was $6.79 in the past 12 months.
What is Abcellera Biologics, Inc.’s market cap?
Abcellera Biologics, Inc.’s market cap is $1.69B.
When is Abcellera Biologics, Inc.’s upcoming earnings report date?
Abcellera Biologics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were Abcellera Biologics, Inc.’s earnings last quarter?
Abcellera Biologics, Inc. released its earnings results on May 11, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.171 by $0.031.
Is Abcellera Biologics, Inc. overvalued?
According to Wall Street analysts Abcellera Biologics, Inc.’s price is currently Undervalued.
Does Abcellera Biologics, Inc. pay dividends?
Abcellera Biologics, Inc. does not currently pay dividends.
What is Abcellera Biologics, Inc.’s EPS estimate?
Abcellera Biologics, Inc.’s EPS estimate is -0.14.
How many shares outstanding does Abcellera Biologics, Inc. have?
Abcellera Biologics, Inc. has 305,375,400 shares outstanding.
What happened to Abcellera Biologics, Inc.’s price movement after its last earnings report?
Abcellera Biologics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.171. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of Abcellera Biologics, Inc.?
Currently, no hedge funds are holding shares in ABCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.40 (134.41% Upside)
$9.40 (134.41% Upside)
Blogger Sentiment
Neutral
ABCL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $95.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.36%
12-Months-Change
Fundamentals
Return on Equity
-14.86%
Trailing 12-Months
Asset Growth
-2.76%
Trailing 12-Months
Company Description
Abcellera Biologics, Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
ABCL Company Deck
ABCL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive clinical and financial picture: compelling interim Phase I data for ABCL635 (favorable tolerability, strong PK/PD and sustained target engagement) with a clear near-term Phase II catalyst (Q3 2026), expanding pipeline progress, and a robust liquidity position (~$655M available including government funding). Headwinds include continued quarterly losses (~$43M), modest current revenue (~$8M) with expected declines in partner-derived research fees, a small potential tolerability signal at the highest dose (900 mg), blinded MAD data limiting full visibility, and remaining scientific/efficacy risk until Phase II readout. Overall, positives (clinical momentum, liquidity, and pipeline cadence) outweigh the negatives, but the company remains dependent on upcoming Phase II and other near-term milestones.View all ABCL earnings summariesABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$9.40
▲(134.41% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
40.93% Insiders
4.67% Mutual Funds
19.86% Other Institutional Investors
33.18% Public Companies and Individual Investors